DH investigates case of severe paediatric influenza A infection
The Centre for Health Protection (CHP) of the Department of Health is today (August 9) investigating a severe paediatric influenza A infection case. The CHP urged the public to maintain good personal and environmental hygiene at all times to prevent influenza and other respiratory illnesses.
The case involves a 5-year-old girl with underlying illnesses. She developed a fever, cough with sputum, chills, rigors, and shortness of breath on August 7. She was taken to the Accident and Emergency Department of Tuen Mun Hospital yesterday (August 8) and was admitted to the paediatric intensive care unit for treatment. Her respiratory specimen tested positive for influenza A (H1) virus. Her clinical diagnosis was influenza A infection complicated with sepsis. She remains hospitalised and is in serious condition.
The CHP's preliminary investigation revealed that the girl had received the 2025/26 seasonal influenza vaccination. She had no travel history during the incubation period. Her household contacts remain asymptomatic.The CHP will continue to investigate the case.
"Hong Kong entered the influenza season in late June. The latest surveillance data showed that the influenza activity is at a high level currently. The percentage of respiratory specimens testing positive for seasonal influenza viruses was 9.94 per cent and the influenza admission rate in public hospitals was 0.73 cases per 10 000 population last week. The predominant influenza viruses detected were influenza A (H3) and influenza A (H1) (45 per cent each), the rest were influenza B (10 per cent). We expect the level of influenza activity to remain high in the coming weeks," said the Controller of the CHP, Dr Edwin Tsui.
"The World Health Organization has already announced its recommendations for the composition of influenza vaccines for the 2026/27 season in the northern hemisphere. Vaccine manufacturers are currently producing vaccines in accordance with the recommendations for use by the end of the year. The Government has completed the procurement process for the 2026/27 Seasonal Influenza Vaccination Programmes and is actively preparing various vaccination arrangements. In addition, influenza and COVID-19 activities are at a high level currently, I urge members of the public, especially children, the elderly and high-risk groups such as those with underlying illnesses or compromised immune systems, to seek medical attention and treatment as soon as possible if they develop a fever or respiratory symptoms, as their condition may deteriorate rapidly. This will help reduce the risk of complications. If you live with members of high-risk groups, you should wear a surgical mask at home and seek medical attention as soon as possible if you develop respiratory symptoms to reduce the risk of infecting them. Other effective ways to reduce the spread of the disease include maintaining household hygiene, frequently cleaning and disinfecting frequently touched surfaces, practising good hand hygiene, and ensuring proper indoor air circulation," he added.
Dr Tsui also reminded parents that the health condition of children with influenza can deteriorate rapidly. Parents must pay close attention to their condition, and visit an accident and emergency department immediately if the child's condition deteriorates with symptoms such as shortness of breath, wheezing, blue lips, chest pain, confusion, a persistent fever or convulsions.
Members of the public may refer to the CHP's COVID-19 & Flu Express, Seasonal Influenza Webpage and COVID-19 Vaccination Programme Webpage, for the latest information.
The Centre for Health Protection, Photo source: reference image
Director of Health signs co-operation agreement on research for testing and standards of Chinese medicines with NMPA and attends Beijing-Hong Kong Health Cooperation Exchange Conference co-hosted with BJHC in Beijing
The Director of Health, Dr Ronald Lam, led a delegation from the Department of Health (DH) to Beijing today (September 9) to pay a visit to the National Medical Products Administration (NMPA). In addition to exchanging information on the latest progress in promoting scientific regulation and innovation in drugs and medical devices, both sides also signed a co-operation agreement to further deepen collaborations and exchanges in testing technologies of Chinese medicine (CM) and the internationalisation of CM standards. On the same day, the DH and the Beijing Municipal Health Commission (BJHC) co-hosted the Beijing-Hong Kong Health Cooperation Exchange Conference, with a view to jointly advancing the high-quality healthcare development in Hong Kong.
Witnessed by the Commissioner of the NMPA, Mr Huang Guo, Dr Lam and the Director General of the Hong Kong, Macao and Taiwan Affairs Office of the NMPA, Ms He Li, signed a co-operation agreement on research for CM testing and standards to further extend and deepen collaboration in this area, which has spanned more than a decade.
Under the co-operation agreement, both sides will strengthen exchanges and collaborations in the standards and technologies of CM covering research on and formulation of standards for Chinese Materia Medica, CM decoction pieces, proprietary CM and CM granules; the development of testing technologies; as well as safety tests and risk control for the quality of CM, through multiple channels such as expert meetings, seminars and training. Both sides will also deepen talent training and technical interfacing in accordance with the co-operation agreement, with a view to promoting CM standards and testing technology innovation in alignment with international standards.
Dr Lam thanked the NMPA and its affiliated institution, the National Institute for Drug Control (NIDC), for their longstanding support for CM development in the Hong Kong Special Administrative Region. The permanent building of the Government Chinese Medicines Testing Institute under the DH commenced operations late last year. The Chinese Medicines Herbarium inside has received professional technical guidance from the NMPA and the NIDC, and was endowed with more than 300 valuable and representative specimens of Chinese Materia Medica commonly used nationwide, enriching its collections and enhancing public understanding of CM.
Dr Lam remarked that the Outline of the National 15th Five-Year Plan has promulgated to advance the inheritance and innovation of CM and to promote its global expansion. The DH will actively leverage its technical strengths in CM testing and quality control to become an important anchor for CM going global, and to strengthen the exploration, utilisation and research of global medicinal resources. This co-operation arrangement will extend the longstanding close collaboration, and further enhance testing expertise level as well as quality and safety control of CM to promote the development of Hong Kong as a bridgehead for CM going global.
Regarding scientific regulation and innovative development of drugs and medical devices, Dr Lam also introduced the establishment of the Hong Kong Centre for Medical Products Regulation, the preparatory work for the 30th Global Harmonization Working Party Annual Meeting and Technical Committee Meeting scheduled for December this year, and the progress of the 2026 annual bilateral work plan, covering issues on strengthening cross-boundary drug regulation and enhancing training and exchanges between the two sides in different areas such as primary evaluation of new drugs and Good Clinical Practice (GCP) for clinical trials of pharmaceutical products.
In the afternoon of the same day, upon the invitation of the BJHC, the DH co-hosted the annual Beijing-Hong Kong Health Cooperation Exchange Conference during the 2026 China International Fair for Trade in Services. Other co-organisers included the Hong Kong Hospital Authority, the Beijing Municipal Administration of Traditional Chinese Medicine, the Beijing Municipal Disease Prevention and Control Administration, the Beijing Hospitals Authority and the Cross-straits Medicine Exchange Association. The theme of this year's conference is "Beijing and Hong Kong, Join Hands for a Shared Healthy Future", focusing on discussions of smart healthcare, transformation of scientific achievements, inheritance and innovation of CM and public health emergency response.
Dr Lam said that this year is significant as it marks the beginning of the National 15th Five-Year Plan. Under the principle of complementing each other in bringing about mutual benefits, the DH will continue to promote exchanges and collaborations with Beijing, actively integrate into and serve the overall national development, and implement a health-first development strategy to fully leverage Hong Kong's distinctive advantages of having strong support of the motherland and being closely connected to the world to contribute to a "Healthy China".
At the meeting, DH representatives shared how, under the framework of building a health big data ecosystem, Hong Kong's Electronic Health System (eHealth) connects the public and private healthcare sectors to enable realtime sharing of electronic health records, empower citizens to manage their own health, and optimise the allocation of healthcare resources through bigdata analytics. They also introduced Hong Kong's CM regulatory regime and the formulation of CM standards and advancing innovations in testing. Representatives also highlighted Hong Kong's commitment to strengthening primary healthcare under the guiding principle of "prevention first, community-based". The reform is being deepened through chronic disease co-care, intensified tobacco control, and the development of community networks. These measures aim to integrate health management into daily life and encourage citizens to take on the role of being the "first person responsible" for their own health.
During Dr Lam's stay in Beijing, he will also attend some activities on Health and Wellness Service at the 2026 China International Fair for Trade in Services, and pay a visit to related public health authorities.
Director of Health signs co-operation agreement on research for testing and standards of Chinese medicines with NMPA and attends Beijing-Hong Kong Health Cooperation Exchange Conference co-hosted with BJHC in Beijing Source: HKSAR Government Press Releases
Director of Health signs co-operation agreement on research for testing and standards of Chinese medicines with NMPA and attends Beijing-Hong Kong Health Cooperation Exchange Conference co-hosted with BJHC in Beijing Source: HKSAR Government Press Releases
Director of Health signs co-operation agreement on research for testing and standards of Chinese medicines with NMPA and attends Beijing-Hong Kong Health Cooperation Exchange Conference co-hosted with BJHC in Beijing Source: HKSAR Government Press Releases
